Skip to main content

Table 4 Risk of adverse events in studies assessing aspirin in patients with diabetes for the primary prevention of major adverse cardiovascular events

From: Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Study and Year

Total Patients with Diabetes

All Bleeding (ASA)

All Bleeding (Control)

All GI Bleeding (ASA)

All GI Bleeding (Control)

Non-bleeding GI symptoms (ASA)

Non-bleeding GI symptoms (Control)

PHS, 1989

533

-

-

-

-

-

-

ETDRS, 1992

3711

37

37

-

-

-

-

HOT, 1998

1501

-

-

-

-

-

-

PPP, 2003

1031

10

1

8

1

-

-

WHS, 2005

1027

-

-

-

-

-

-

POPADAD, 2008

1276

-

-

28

31

73

94

JPAD, 2008

2539

34

10

12

4

47

4

Number of Events/Number of Participants

-

81/3637

48/3644

48/2419

36/2427

120/1900

98/1915

Pooled RR (95% CI)

-

2.50 (0.77-8.10)

2.13 (0.63-7.25)

2.92 (0.17-50.23)

  1. ASA: aspirin, GI: gastrointestinal, PHS: Physicians' Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP: Primary Prevention Project, WHS: Women's' Health Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes, RR = relative risk (RRs >1 indicate increase risk of an adverse event associated with aspirin).
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840